
SAN DIEGO – (Newswire) – Bionano Genomics (Nasdaq: BNGO) shares taken off today after the recent published results of a genome analysis of Professor Temple Grandin.
Grandin, who has autistic spectrum condition and describes herself as high-functioning, is known for taking part in research studies to improve her understanding of autism.
In her book that she authored, ‘The Autistic Brain’, Grandin said that she relished to participate in research that would aid scientists’ understanding of autism. In 2006, the autism activist received an MRI scan that showed how her amygdala was larger than neurotypical controls.
This evaluation by Bionano Genomics identified novel variants in known autism ‘risk genes’ and other genetic variants important to Temple’s health and wellness. Despite Grandin’s high level of functioning and acute awareness of how her autism manifests, these findings have apparently led to improved clinical management of many of her symptoms.
This evaluation by Bionano Genomics revealed three sequence variations in autism genes. One of the affected genes was found to affect autism while two neurodevelopmental genes which could affect an individuals autism.
When asked to comment, Professor Grandin said, “When I originally requested to have genetic testing, I had no idea that the test I was getting for autism information would provide me with valuable information for other health problems.
“It is clearly beneficial for individuals to undergo genetic testing. Those with autism, like myself, may learn important information to guide medical decisions that may possibly save their lives while also potentially finding a genetic link to autism.”
Eric Holmlin, PhD, CEO of Bionano Genomics says he believes that this publication shows the importance of genetic testing for autism spectrum conditions and neurodevelopmental disorders.
“Widespread adoption of genetic testing is important to patients and families because it creates a better understanding of ASD.
“But more importantly, informs families and patients about immediate health risks associated with ASD that could personalize treatment options and provide potentially life-saving information.”
Bionano Genomics plans to expand upon the publication, and expects to learn more about the condition because of this process.
BNGO stock saw heavy trading today, which rocketed to a high of $7.24 before averaging out $3.54 a share higher than the previous close of $3.08 a share.
The company was bouyed last week by a Nasdaq Exchange update by getting an extension to allow its shares to stay on the market for longer, and with the healthcare company posting positive momentum like this, it should not have to worry about delisting anytime soon.
BNGO stock was up 112.34% as of Monday afternoon.